More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its...

|About: Optimer Pharmaceuticals, Inc. (OPTR)|By:, SA News Editor

More on Optimer Pharmaceuticals (OPTR): Q4 beats revenue expectations as the early launch of its new drug Dificid adds $11M in sales to its top line. Shares +0.9% AH.